• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lexaria Bioscience Corp (NQ: LEXX )

    2.231 +0.001 (+0.02%)
    Streaming Delayed Price Updated: 10:48 AM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Lexaria Bioscience Corp

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test Results
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
    Via ACCESSWIRE
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    First Results from Lexaria's Second GLP-1 Human Pilot Study
    Via ACCESSWIRE
    Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
    Via ACCESSWIRE
    Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
    Via ACCESSWIRE
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Validates Technology’s Superiority, Moving Closer to a Share in the Global Diabetes Treatment Market
    Via Investor Brand Network
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Study Results Supporting Potential Utility of DehydraTECH-CBD in Diabetes Control
    Via Investor Brand Network
    Topics Animal Testing Intellectual Property
    Exposures Animal Testing Intellectual Property
    Positive Results from Lexaria's Molecular Characterization Study
    Via ACCESSWIRE
    Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
    Via ACCESSWIRE
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
    Via Investor Brand Network
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
    Via CannabisNewsWire
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Work with Tirzepatide Molecule
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Oral GLP-1 Alternatives for Diabetes and Obesity Treatment
    Via Investor Brand Network
    Lexaria Preparing For Strategic Growth
    Via ACCESSWIRE
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Q3 2024 Financial Results; Offers a Roadmap for its Key GLP-1 Study Program
    Via Investor Brand Network
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments
    Via CannabisNewsWire
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments
    Via Investor Brand Network
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases “Noteworthy” Weight-Loss Results from Recent Animal Study
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Produces Notable Findings in Latest Weight Loss Study
    Via Investor Brand Network
    Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing
    Via CannabisNewsWire
    Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing
    Via Investor Brand Network
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Issuance of Three New Patents, Growing Portfolio to 46 Granted Patents Worldwide
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study
    Via Investor Brand Network
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.